👵👵👵👩‍�_老虎社区_美港股上老虎

道琼斯工业平均指数
2022-07-07

👵👵👵👩‍👩‍👦‍👦👖👕一一：👮8@123是是是*；

InflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder

Grandbrothers The U.S. Food and Drug Administration (FDA) granted fast track designation to InflaR

InflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":681795406,"tweetId":"681795406","gmtCreate":1657162575609,"gmtModify":1704866721465,"author":{"id":3551449686726984,"idStr":"3551449686726984","authorId":3551449686726984,"authorIdStr":"3551449686726984","name":"道琼斯工业平均指数","avatar":"https://static.tigerbbs.com/918d9a8a8166958e94c7f6e8ccc65d70","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":15,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>👵👵👵👩‍👩‍👦‍👦👖👕一一：👮8<a href=\"https://laohu8.com/U/3573704321965451\">@123是是是</a>*；</p></body></html>","htmlText":"<html><head></head><body><p>👵👵👵👩‍👩‍👦‍👦👖👕一一：👮8<a href=\"https://laohu8.com/U/3573704321965451\">@123是是是</a>*；</p></body></html>","text":"👵👵👵👩‍👩‍👦‍👦👖👕一一：👮8@123是是是*；","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/681795406","repostId":2249517541,"repostType":2,"repost":{"id":"2249517541","kind":"highlight","pubTimestamp":1657108048,"share":"https://www.laohu8.com/m/news/2249517541?lang=&edition=full","pubTime":"2022-07-06 19:47","market":"us","language":"en","title":"InflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2249517541","media":"seekingalpha","summary":"Grandbrothers \n The U.S. Food and Drug Administration (FDA) granted fast track designation to InflaR","content":"<html><body><p><figure> <picture> <img height=\"1024px\" sizes=\"(max-width: 768px) calc(100vw - 36px), (max-width: 1024px) calc(100vw - 132px), (max-width: 1200px) calc(66.6vw - 72px), 600px\" src=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg?io=getty-c-w750\" srcset=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg?io=getty-c-w1536 1536w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg?io=getty-c-w1280 1280w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg?io=getty-c-w1080 1080w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg?io=getty-c-w750 750w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg?io=getty-c-w640 640w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg?io=getty-c-w480 480w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg?io=getty-c-w320 320w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg?io=getty-c-w240 240w\" width=\"1536px\"/> </picture> <figcaption><p>Grandbrothers</p></figcaption> </figure></p>\n<ul> <li>The U.S. Food and Drug Administration (FDA) granted fast track designation to InflaRx's (<span>NASDAQ:IFRX</span>) vilobelimab to treat ulcerative pyoderma gangrenosum (PG).</li>\n<li>PG is a rare disorder which causes large, painful ulcers to develop on the skin, often on the legs.</li>\n<li>The company had had submitted a request for a fast track designation after positive data in a phase 2a trial in PG, Germany-based InflaRx said in a July 6 press release.</li>\n<li>Vilobelimab has already received orphan drug status for PG in the U.S. and EU.</li>\n<li>IFRX <font color=\"green\">+14.08%</font> to $1.62 premarket July 6</li>\n</ul></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>InflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-07-06 19:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3854518-inflarx-stock-rises-14-as-vilobelimab-gets-fda-fast-track-status><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Grandbrothers \n The U.S. Food and Drug Administration (FDA) granted fast track designation to InflaRx's (NASDAQ:IFRX) vilobelimab to treat ulcerative pyoderma gangrenosum (PG).\nPG is a rare disorder ...</p>\n\n<a href=\"https://seekingalpha.com/news/3854518-inflarx-stock-rises-14-as-vilobelimab-gets-fda-fast-track-status\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4504":"桥水持仓","BK4550":"红杉资本持仓","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4558":"双十一","BK4581":"高盛持仓","BK4139":"生物科技","PG":"宝洁","IFRX":"InflaRx N.V.","BK4567":"ESG概念","BK4018":"居家用品","BK4559":"巴菲特持仓"},"source_url":"https://seekingalpha.com/news/3854518-inflarx-stock-rises-14-as-vilobelimab-gets-fda-fast-track-status","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2249517541","content_text":"Grandbrothers \n The U.S. Food and Drug Administration (FDA) granted fast track designation to InflaRx's (NASDAQ:IFRX) vilobelimab to treat ulcerative pyoderma gangrenosum (PG).\nPG is a rare disorder which causes large, painful ulcers to develop on the skin, often on the legs.\nThe company had had submitted a request for a fast track designation after positive data in a phase 2a trial in PG, Germany-based InflaRx said in a July 6 press release.\nVilobelimab has already received orphan drug status for PG in the U.S. and EU.\nIFRX +14.08% to $1.62 premarket July 6","news_type":1},"isVote":1,"tweetType":1,"viewCount":1439,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":41,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}